ESC高血压委员会与EAPCI关于肾去神经术治疗成人高血压的临床共识声明
该共识由ESC高血压委员会与EAPCI制定,基于2018年ESC/ESH指南后发表的随机假手术对照试验,确认射频和超声肾去神经术(RDN)在包括难治性高血压在内的广泛高血压患者中具有降压疗效和安全性。共识提出RDN可作为经动态血压监测确认的难治性高血压的辅助治疗选择,也可用于无法长期耐受降压药的患者,并强调共同决策和多学科团队评估。
要点
- RDN可作为经动态血压监测确认的难治性高血压的辅助治疗选择。
- RDN也可用于无法长期耐受降压药物的高血压患者。
- 决策需结合患者整体心血管风险及高血压介导的器官损害或心血管并发症。
核心结论
- RDN是经动态血压监测确认的难治性高血压的辅助治疗选择,也可用于无法长期耐受降压药的患者。
研究设计与样本
- ESC高血压委员会与EAPCI专家组的临床共识声明,基于2018年ESC/ESH指南后发表的高质量研究,包括随机假手术对照试验。
主要发现
- 随机假手术对照试验确认射频和超声RDN在包括难治性高血压在内的广泛高血压患者中具有降压疗效和安全性。
关键数值与推荐
- RDN适用于经动态血压监测确认的难治性高血压,尽管已尽力进行生活方式和药物治疗。
- RDN可用于无法长期耐受降压药的患者。
- 决策过程应考虑患者整体心血管风险和/或高血压介导的器官损害或心血管并发症。
- 多学科高血压团队评估适应证并促进RDN操作。
- 介入医生需具备肾脏介入专长和RDN专项培训,中心需具备处理潜在并发症的技能和资源。
临床怎么用
- 对经动态血压监测确认的难治性高血压患者,在充分生活方式和药物治疗后,可考虑RDN作为辅助治疗。
- 对无法长期耐受降压药的患者,可考虑RDN。
- 实施RDN需经多学科高血压团队评估,并开展共同决策,确保患者充分了解获益与局限。
局限性
- 未来需研究RDN降压对临床结局的影响及高血压以外的潜在临床适应证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the publication of the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) Guidelines for the Management of Arterial Hypertension, several high-quality studies, including randomised, sham-controlled trials on catheter-based renal denervation (RDN) were published, confirming both the blood pressure (BP)-lowering efficacy and safety of radiofrequency and ultrasound RDN in a broad range of patients with hypertension, including resistant hypertension. A clinical consensus document by the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) on RDN in the management of hypertension was considered necessary to inform clinical practice. This expert group proposes that RDN is an adjunct treatment option in uncontrolled resistant hypertension, confirmed by ambulatory BP measurements, despite best efforts at lifestyle and pharmacological interventions. RDN may also be used in patients who are unable to tolerate antihypertensive medications in the long term. A shared decision-making process is a key feature and preferably includes a patient who is well informed on the benefits and limitations of the procedure. The decision-making process should take (i) the patient's global cardiovascular (CV) risk and/or (ii) the presence of hypertension-mediated organ damage or CV complications into account. Multidisciplinary hypertension teams involving hypertension experts and interventionalists evaluate the indication and facilitate the RDN procedure. Interventionalists require expertise in renal interventions and specific training in RDN procedures. Centres performing these procedures require the skills and resources to deal with potential complications. Future research is needed to address open questions and investigate the impact of BP-lowering with RDN on clinical outcomes and potential clinical indications beyond hypertension.
引用
- Barbato, Azizi, Schmieder, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023. PMID: 36790101. doi:10.1093/eurheartj/ehad054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。